UW Study Recruits Gambling + GLP-1 Users for Addiction Research 2026

University of Washington seeks gambling + GLP-1 users for GAME Study exploring addiction patterns and behavioral health.

Sofia Eriksson

Sofia Eriksson

Senior Reporter

3 min read
23
0
UW Study Recruits Gambling + GLP-1 Users for Addiction Research 2026

The Addictions, Drug & Alcohol Institute (ADAI) at the University of Washington has launched a research initiative called the GAME Study, recruiting participants who engage in gambling activities while taking GLP-1 receptor agonist medications—a class of drugs commonly prescribed for weight management and diabetes control.

Participants will receive compensation for their involvement in the study, which aims to explore potential correlations between GLP-1 medication use and gambling behavior. The research represents one of the first academic investigations into how increasingly popular weight-loss pharmaceuticals may intersect with addiction-related behaviors including gambling.

Market Context and Timing

GLP-1 medications, including brand names like Ozempic and Wegovy, have experienced explosive growth in public awareness and prescription rates over the past 18 months. Simultaneously, gambling participation—both in casinos and online—continues to expand across North America. The GAME Study essentially asks: as millions of Americans adopt GLP-1 medications, does their gambling engagement change, and if so, how?

The research addresses a gap in existing addiction literature. Most contemporary harm-reduction frameworks assume relatively static individual susceptibility to gambling-related problems. However, if GLP-1 medications alter impulse control, dopamine sensitivity, or behavioral reward mechanisms, then existing responsible gaming protocols may require recalibration.

Implications for Gaming Operators

For casinos and iGaming platforms, the GAME Study's findings could inform customer risk profiling and responsible gaming interventions. If the research identifies that GLP-1 users exhibit elevated gambling risk or reduced inhibitory control, operators may need to:

  • Develop targeted responsible gaming messaging for this demographic
  • Adjust bonus structures or promotional intensity for identified risk groups
  • Enhance monitoring systems to flag customers in this category for proactive outreach
  • Train customer service and compliance teams on GLP-1-related behavioral health considerations

Responsible Gaming Evolution

The research also reflects a broader evolution in harm minimization. Industry best practices increasingly rely on behavioral data, pharmaceutical history, and health status indicators to personalize responsible gaming measures. Rather than applying one-size-fits-all limits, operators can use demographic and medical information to calibrate risk management.

This approach raises privacy considerations, particularly around pharmaceutical data handling and customer consent. However, operators that proactively engage with health-related research may strengthen their regulatory standing and demonstrate commitment to evidence-based harm reduction.

What to Watch

The GAME Study's recruitment phase is now underway. Industry observers should monitor: (1) whether the study identifies significant behavioral patterns; (2) whether findings are peer-reviewed and published in addiction or gaming literature; and (3) whether major operators or gaming associations incorporate GLP-1 considerations into responsible gaming frameworks. The research could become a foundation for updated industry guidelines and regulatory expectations around pharmaceutical-behavioral health intersections.

Source: casino.org

harm-minimizationaddiction-researchGLP-1-medicationsbehavioral-healthresponsible-gamingacademic-study2026public-health
Sofia Eriksson

Sofia Eriksson

Senior Reporter

Member of the iGaming Pulse editorial team. Covering industry news, analysis, and B2B developments across the global iGaming sector.

0 Comments

Leave a Comment

Related Articles

Newsletter

Stay ahead of the iGaming industry

Weekly briefings covering regulation, operator moves, B2B deals, and market analysis — delivered free to your inbox every Thursday.

No spam. Unsubscribe at any time. 5,000+ industry professionals already subscribed.